A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate Tarceva in a selected population of patients with untreated advanced
non-small cell lung cancer who are anticipated to have a relatively good (indolent) prognosis
based on clinical criteria. It is anticipated that selection will enrich for tumor
characteristic that are likely to be benefited by EGFR inhibitor treatment (survival greater
than 90 days). The goal of this strategy is to provide a less toxic, oral treatment for
patients with advanced NSCLC that will not interfere with patients receiving chemotherapy at
some point in the future and may prolong the time to chemotherapy related progression.
Patients will remain on study until disease progresses, a decline in performance status, if
patient cannot tolerate the side effects or develops symptoms requiring conventional
chemotherapy.